WO2002090566A3 - Recombinant tumor specific antibody and use thereof - Google Patents
Recombinant tumor specific antibody and use thereof Download PDFInfo
- Publication number
- WO2002090566A3 WO2002090566A3 PCT/US2002/013844 US0213844W WO02090566A3 WO 2002090566 A3 WO2002090566 A3 WO 2002090566A3 US 0213844 W US0213844 W US 0213844W WO 02090566 A3 WO02090566 A3 WO 02090566A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- specific antibody
- tumor specific
- antibodies
- recombinant tumor
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60239454T DE60239454D1 (en) | 2001-05-03 | 2002-05-03 | RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE |
CA2446087A CA2446087C (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor specific antibody and use thereof |
PL367831A PL205352B1 (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor specific antibody and use thereof |
AT02769304T ATE502053T1 (en) | 2001-05-03 | 2002-05-03 | RECOMBINANT TUMOR-SPECIFIC ANTIBODIES AND USE THEREOF |
JP2002587625A JP4309662B2 (en) | 2001-05-03 | 2002-05-03 | Tumor-specific recombinant antibodies and uses thereof |
EP02769304A EP1383785B1 (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor specific antibody and use thereof |
AU2002308562A AU2002308562B2 (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor specific antibody and use thereof |
HU0400284A HUP0400284A3 (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor specific antibody and use thereof |
DK02769304.3T DK1383785T3 (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor-specific antibody and its use |
BR0209177-1A BR0209177A (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor specific antibody and use |
MXPA03009924A MXPA03009924A (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor specific antibody and use thereof. |
KR1020037014151A KR100900166B1 (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor specific antibody and use thereof |
ZA2003/09380A ZA200309380B (en) | 2001-05-03 | 2003-12-02 | Recombinant tumor specific antibody and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28856401P | 2001-05-03 | 2001-05-03 | |
US60/288,564 | 2001-05-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002090566A2 WO2002090566A2 (en) | 2002-11-14 |
WO2002090566A3 true WO2002090566A3 (en) | 2003-07-17 |
Family
ID=23107653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/013844 WO2002090566A2 (en) | 2001-05-03 | 2002-05-03 | Recombinant tumor specific antibody and use thereof |
Country Status (19)
Country | Link |
---|---|
US (3) | US6969517B2 (en) |
EP (1) | EP1383785B1 (en) |
JP (2) | JP4309662B2 (en) |
KR (1) | KR100900166B1 (en) |
CN (1) | CN100503639C (en) |
AT (1) | ATE502053T1 (en) |
AU (1) | AU2002308562B2 (en) |
BR (1) | BR0209177A (en) |
CA (1) | CA2446087C (en) |
DE (1) | DE60239454D1 (en) |
DK (1) | DK1383785T3 (en) |
ES (1) | ES2361664T3 (en) |
HU (1) | HUP0400284A3 (en) |
MX (1) | MXPA03009924A (en) |
PL (1) | PL205352B1 (en) |
PT (1) | PT1383785E (en) |
RU (1) | RU2306320C9 (en) |
WO (1) | WO2002090566A2 (en) |
ZA (1) | ZA200309380B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8907066B2 (en) | 2009-04-22 | 2014-12-09 | Merck Patent Gmbh | Antibody fusion proteins with a modified FcRn binding site |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1037927T3 (en) | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
EP1071468B1 (en) * | 1998-04-15 | 2006-06-14 | Lexigen Pharmaceuticals Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
EP1187852B1 (en) * | 1999-05-19 | 2007-08-08 | EMD Lexigen Research Center Corp. | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
ATE316982T1 (en) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | MULTIPLE CYTOKINE ANTIBODIES COMPLEXES |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
DE60122286T2 (en) * | 2000-02-11 | 2007-08-02 | Merck Patent Gmbh | INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS |
BR0112111A (en) * | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers |
CA2440221C (en) | 2001-03-07 | 2013-02-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (en) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE |
US8986944B2 (en) | 2001-10-11 | 2015-03-24 | Aviva Biosciences Corporation | Methods and compositions for separating rare cells from fluid samples |
US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
WO2003048334A2 (en) * | 2001-12-04 | 2003-06-12 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
AT502293B1 (en) * | 2002-05-15 | 2008-03-15 | Igeneon Krebs Immuntherapie | IMMUNOGENERAL, MONOCLONAL ANTIBODY |
CA2510180C (en) | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
PT2829283T (en) | 2003-04-30 | 2017-09-08 | Univ Zuerich | Methods for treating cancer using an immunotoxin |
AT500651B9 (en) * | 2003-05-27 | 2010-04-15 | Altropus Gmbh | ACTIVE IMMUNIZING ANTIBODY |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
WO2005063820A2 (en) | 2003-12-30 | 2005-07-14 | Merck Patent Gmbh | Il-7 fusion proteins |
EP1699821B1 (en) | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
WO2005066348A2 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US20050180979A1 (en) * | 2004-02-13 | 2005-08-18 | Micromet Ag | Anti-EpCAM immunoglobulins |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
EP3061461A1 (en) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
KR20070085886A (en) * | 2004-12-09 | 2007-08-27 | 메르크 파텐트 게엠베하 | Il-7 variants with reduced immunogenicity |
ES2449195T3 (en) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Glycopegylated granulocyte colony stimulating factor |
WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
WO2007063825A1 (en) | 2005-11-29 | 2007-06-07 | Japan Science And Technology Agency | Monoclonal antibody directed against cd166 and method for production thereof |
JP2009519024A (en) * | 2005-12-15 | 2009-05-14 | マイクロメット アクツィエン ゲゼルシャフト | Domain-grafted antibody |
JP5175214B2 (en) * | 2005-12-30 | 2013-04-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Interleukin-12P40 variant with improved stability |
JP2009521909A (en) * | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-IL-6 antibody that inhibits binding of IL-6 and IL-6Rα complex to gp130 |
BRPI0620795A2 (en) | 2005-12-30 | 2011-11-22 | Merck Patent Ges Mit Beschronkter Haftung | anti-cd19 antibodies reduced immunogenicity |
ES2395969T3 (en) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Genetically modified heterodimeric protein domains |
AU2007271398B2 (en) * | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
EP2041299A4 (en) | 2006-07-14 | 2010-01-13 | Aviva Biosciences Corp | Methods and compositions for detecting rare cells from a biological sample |
US20080274958A1 (en) | 2006-07-21 | 2008-11-06 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
NZ580030A (en) | 2007-04-03 | 2012-06-29 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
KR101582841B1 (en) | 2008-02-27 | 2016-01-11 | 노보 노르디스크 에이/에스 | Conjugated factor viii molecules |
EA201071226A1 (en) * | 2008-04-25 | 2011-06-30 | Мерк Патент Гмбх | ARTIFICIAL FRAMEWORK PROTEIN |
GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
WO2011032296A1 (en) | 2009-09-21 | 2011-03-24 | Mount Sinai Hospital | Methods and compositions for the diagnosis and treatment of thyroid cancer |
US20110275530A1 (en) | 2010-05-04 | 2011-11-10 | Paul Walfish | Methods and compositions for the diagnosis and treatment of epithelial cancers |
CN102174465A (en) * | 2011-01-12 | 2011-09-07 | 武汉格蓝丽富科技有限公司 | Method for separating enriched target cells from tissues |
EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
CN103998932B (en) * | 2011-06-29 | 2017-06-06 | 中央研究院 | Capture, purifying and release using face coat to biological substance |
EP2748197A2 (en) | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
JP6163502B2 (en) * | 2012-03-02 | 2017-07-12 | アカデミア シニカAcademia Sinica | Anti-epithelial cell adhesion molecule (EpCAM) antibody and method of use thereof |
US9494500B2 (en) | 2012-10-29 | 2016-11-15 | Academia Sinica | Collection and concentration system for biologic substance of interest and use thereof |
SG11201506451UA (en) | 2013-03-06 | 2015-09-29 | Merrimack Pharmaceuticals Inc | Anti-c-met tandem fc bispecific antibodies |
CA2925915C (en) * | 2013-10-02 | 2023-05-02 | Viventia Bio Inc. | Anti-epcam antibodies and methods of use |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
TW201623605A (en) | 2014-04-01 | 2016-07-01 | 中央研究院 | Methods and systems for cancer diagnosis and prognosis |
EP2998026B1 (en) | 2014-08-26 | 2024-01-17 | Academia Sinica | Collector architecture layout design |
CA2979400A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
CN108513547A (en) | 2015-03-12 | 2018-09-07 | 维文蒂亚生物公司 | Therapy for EPCAM positive carcinomas of urinary bladder |
US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
EP3630163A4 (en) * | 2017-05-24 | 2021-06-09 | Pandion Operations, Inc. | Targeted immunotolerance |
CN108503714A (en) * | 2018-04-10 | 2018-09-07 | 浙江科途医学科技有限公司 | A kind of human interleukin 2 and anti-human signal transduction factor scfv fusion protein and its application |
WO2020131697A2 (en) | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
Family Cites Families (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US73627A (en) * | 1868-01-21 | Improved paint-compound | ||
US348237A (en) * | 1886-08-31 | richards | ||
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
KR850004274A (en) | 1983-12-13 | 1985-07-11 | 원본미기재 | Method for preparing erythropoietin |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US5082658A (en) | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
EP0158198A1 (en) | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA and use thereof |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
US5643565A (en) | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
DE3712985A1 (en) | 1987-04-16 | 1988-11-03 | Hoechst Ag | BIFUNCTIONAL PROTEINS |
US5359035A (en) | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
EP0237019A3 (en) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interferon conjugate and production thereof using recombinant gene |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DK173067B1 (en) | 1986-06-27 | 1999-12-13 | Univ Washington | Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines |
US4894227A (en) | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5508031A (en) | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
US4732683A (en) | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
DE3853515T3 (en) | 1987-05-21 | 2005-08-25 | Micromet Ag | MULTIFUNCTIONAL PROTEINS WITH SPECIFIC OBJECTIVES. |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
EP0294703B1 (en) | 1987-06-10 | 1995-05-10 | Dana-Farber Cancer Institute, Inc. | Bifunctional antibody constructs and method for selectively destroying cell populations |
US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
PH26813A (en) | 1987-09-02 | 1992-11-05 | Ciba Geigy Ag | Conjugates of cytokines with immunoglobulins |
EP0308936B1 (en) | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
PT88641B (en) | 1987-10-02 | 1993-04-30 | Genentech Inc | METHOD FOR PREPARING A VARIETY OF ADHESION |
ZA888978B (en) | 1987-12-04 | 1990-07-25 | Du Pont | Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension |
JP3040121B2 (en) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | Methods of treating tumor cells by inhibiting growth factor receptor function |
CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
US5120525A (en) | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
IT1217724B (en) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | SPECIFIC MONOCLONAL ANTIBODY FOR A SEQUENCE OF FIBRONETIN EXPRESSED IN TRANSFORMED HYBRID CELLS ACCORDING TO SUCH ANTIBODY AND USE OF THE MONOCLONAL ANTIBODY FOR THE DIAGNOSIS OF TUMORS |
IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
ATE123065T1 (en) | 1989-07-07 | 1995-06-15 | Takeda Chemical Industries Ltd | PROTEINS AND THEIR PRODUCTION. |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
KR100263845B1 (en) | 1989-10-13 | 2000-08-16 | 스튜어트 엘.왓트 | Erythropoietin isoforms and preparation method thereof and pharmaceutical composition containing it |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
ATE366311T1 (en) | 1989-12-22 | 2007-07-15 | Hoffmann La Roche | CYTOTOXIC LYMPHOCYTE MATURATION FACTOR 35KD SUBUNIT AND MONOCLONAL ANTIBODIES SPECIFIC THEREOF |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
DE69227693T2 (en) | 1991-08-30 | 1999-07-22 | Hutchinson Fred Cancer Res | HYBRID CYTOKINE |
US20020037558A1 (en) * | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
US6627615B1 (en) * | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
PT633929E (en) | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | METHOD FOR PROLIFERATION (IN VITRO) OF DENTIFICAL CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENES |
EP0615451B1 (en) | 1992-05-26 | 2005-12-07 | Immunex Corporation | Novel cytokine that binds cd30 |
EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
DE69332485T2 (en) | 1992-08-11 | 2003-11-13 | Harvard College | Immunomodulatory peptides |
DE4228839A1 (en) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Methods for the detection and determination of mediators |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
CA2147499C (en) | 1992-11-05 | 2010-10-19 | Ron S. Israeli | Prostate-specific membrane antigen |
US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5738852A (en) | 1993-04-20 | 1998-04-14 | Solis Therapeutics, Inc. | Methods of enhancing antigen-specific T cell responses |
US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
HUT73876A (en) | 1993-04-29 | 1996-10-28 | Abbott Lab | Erythropoietin analog compositions and methods |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
JP3880064B2 (en) | 1994-04-26 | 2007-02-14 | ザ チルドレンズ メディカル センター コーポレイション | Angiostatin and its use in inhibiting angiogenesis |
CU22615A1 (en) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
DE69523857T2 (en) | 1994-09-16 | 2002-06-13 | Merck Patent Gmbh | immunoconjugates |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US6169070B1 (en) | 1995-03-10 | 2001-01-02 | Genentech, Inc. | Mer receptor activation by gas6 |
US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
KR19990028388A (en) | 1995-06-30 | 1999-04-15 | 피터 지. 스트링거 | How to Treat Diabetes |
US6406689B1 (en) | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
CA2205757C (en) | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
ATE218143T1 (en) * | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | USE OF BI- AND TRISPECIFIC ANTIBODIES TO INDUCE TUMOR IMMUNITY |
US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
US6100387A (en) | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
PT973550E (en) | 1997-04-11 | 2003-01-31 | Searle & Co | ANTI-INTEGRINE ANTIBODIES ANTI-INTEGRINA AVB3 |
US7227002B1 (en) * | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
US5873423A (en) * | 1997-07-31 | 1999-02-23 | Briese Industrial Technologies, Inc. | Frustum cutting bit arrangement |
DK1037927T3 (en) | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation |
US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
EP1071468B1 (en) * | 1998-04-15 | 2006-06-14 | Lexigen Pharmaceuticals Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
CA2328081A1 (en) | 1998-04-17 | 1999-10-28 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
AU3655899A (en) | 1998-04-20 | 1999-11-08 | Regents Of The University Of California, The | Modified immunoglobulin molecules and methods for use thereof |
AU751823B2 (en) | 1998-05-14 | 2002-08-29 | Merck Patent Gmbh | Fused protein |
US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
BR9913331A (en) * | 1998-08-25 | 2001-05-15 | Lexigen Pharm Corp | Expression and export of angiogenesis inhibitors as immunofusins |
US6646113B1 (en) * | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
US6335176B1 (en) | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
AU778939B2 (en) * | 1999-01-07 | 2004-12-23 | Emd Lexigen Research Center Corp. | Expression and export of anti-obesity proteins as Fc fusion proteins |
CN101173295A (en) | 1999-05-06 | 2008-05-07 | 威克福雷大学 | Compositions and methods for identifying antigens which elicit an immune response |
US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
EP1187852B1 (en) | 1999-05-19 | 2007-08-08 | EMD Lexigen Research Center Corp. | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythopintin derivatives |
CZ299516B6 (en) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
ATE316982T1 (en) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | MULTIPLE CYTOKINE ANTIBODIES COMPLEXES |
EP1228214A2 (en) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietin forms with improved properties |
US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
DE60122286T2 (en) | 2000-02-11 | 2007-08-02 | Merck Patent Gmbh | INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS |
PT1719528E (en) | 2000-02-24 | 2012-01-06 | Philogen Spa | Compositions and methods for treatment of angiogenesis in pathological lesions |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
WO2001088117A2 (en) | 2000-05-12 | 2001-11-22 | Neose Technologies, Inc. | In vitro fucosylation recombinant glycopeptides |
BR0112111A (en) | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers |
US20040043457A1 (en) * | 2001-01-18 | 2004-03-04 | Silke Schumacher | Bifunctional fusion proteins with glucocerebrosidase activity |
ATE400030T1 (en) * | 2001-02-19 | 2008-07-15 | Merck Patent Gmbh | METHOD FOR IDENTIFYING T CELL PITOPES AND ITS APPLICATION TO PRODUCING MOLECULES WITH REDUCED IMMUNOGENICITY |
MXPA03007323A (en) * | 2001-02-19 | 2003-12-12 | Merck Patent Gmbh | Artificial proteins with reduced immunogenicity. |
CA2440221C (en) | 2001-03-07 | 2013-02-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (en) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE |
TW544602B (en) * | 2001-08-08 | 2003-08-01 | Hon Hai Prec Ind Co Ltd | Delivery notification system |
WO2003048334A2 (en) | 2001-12-04 | 2003-06-12 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
CA2510180C (en) | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
US20050069521A1 (en) | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
WO2005063820A2 (en) | 2003-12-30 | 2005-07-14 | Merck Patent Gmbh | Il-7 fusion proteins |
EP1699821B1 (en) | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
KR20070085886A (en) | 2004-12-09 | 2007-08-27 | 메르크 파텐트 게엠베하 | Il-7 variants with reduced immunogenicity |
US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
JP2009521909A (en) | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-IL-6 antibody that inhibits binding of IL-6 and IL-6Rα complex to gp130 |
BRPI0620795A2 (en) | 2005-12-30 | 2011-11-22 | Merck Patent Ges Mit Beschronkter Haftung | anti-cd19 antibodies reduced immunogenicity |
JP5175214B2 (en) | 2005-12-30 | 2013-04-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Interleukin-12P40 variant with improved stability |
ES2395969T3 (en) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Genetically modified heterodimeric protein domains |
AU2007271398B2 (en) | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
-
2002
- 2002-05-03 DE DE60239454T patent/DE60239454D1/en not_active Expired - Lifetime
- 2002-05-03 EP EP02769304A patent/EP1383785B1/en not_active Expired - Lifetime
- 2002-05-03 JP JP2002587625A patent/JP4309662B2/en not_active Expired - Fee Related
- 2002-05-03 PL PL367831A patent/PL205352B1/en unknown
- 2002-05-03 WO PCT/US2002/013844 patent/WO2002090566A2/en active Application Filing
- 2002-05-03 ES ES02769304T patent/ES2361664T3/en not_active Expired - Lifetime
- 2002-05-03 BR BR0209177-1A patent/BR0209177A/en active Search and Examination
- 2002-05-03 US US10/138,727 patent/US6969517B2/en not_active Expired - Fee Related
- 2002-05-03 CN CNB02809297XA patent/CN100503639C/en not_active Expired - Fee Related
- 2002-05-03 MX MXPA03009924A patent/MXPA03009924A/en active IP Right Grant
- 2002-05-03 CA CA2446087A patent/CA2446087C/en not_active Expired - Fee Related
- 2002-05-03 DK DK02769304.3T patent/DK1383785T3/en active
- 2002-05-03 KR KR1020037014151A patent/KR100900166B1/en not_active IP Right Cessation
- 2002-05-03 RU RU2003132705/13A patent/RU2306320C9/en not_active IP Right Cessation
- 2002-05-03 AT AT02769304T patent/ATE502053T1/en active
- 2002-05-03 PT PT02769304T patent/PT1383785E/en unknown
- 2002-05-03 AU AU2002308562A patent/AU2002308562B2/en not_active Ceased
- 2002-05-03 HU HU0400284A patent/HUP0400284A3/en unknown
-
2003
- 2003-12-02 ZA ZA2003/09380A patent/ZA200309380B/en unknown
-
2005
- 2005-07-01 US US11/174,186 patent/US7459538B2/en not_active Expired - Fee Related
-
2008
- 2008-08-29 US US12/201,935 patent/US7803618B2/en not_active Expired - Fee Related
-
2009
- 2009-03-17 JP JP2009064775A patent/JP4546571B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
CATON ET AL.: "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin", THE EMBO JOURNAL, vol. 5, 1996, pages 1577 - 1587, XP002963047 * |
FELL ET AL.: "Chimeric L6 antitumor antibody", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, 5 August 1992 (1992-08-05), pages 15552 - 15558, XP002963048 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8907066B2 (en) | 2009-04-22 | 2014-12-09 | Merck Patent Gmbh | Antibody fusion proteins with a modified FcRn binding site |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002090566A3 (en) | Recombinant tumor specific antibody and use thereof | |
PL377337A1 (en) | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 | |
WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
WO2005062972A3 (en) | Treatment of cancer with novel anti-il 13 monoclonal antibodies | |
EP2283869A3 (en) | Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer | |
WO2003012072A3 (en) | Monoclonal antibodies to activated erbb family members and methods of use thereof | |
AU2002308348A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
WO2004010947A3 (en) | Humanized antibodies against human 4-1bb | |
WO2004009622A3 (en) | Protein complexes of cellular networks underlying the development of cancer and other diseases | |
MXPA03008739A (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours. | |
WO2006105488A3 (en) | Antibodies and related molecules that bind to 161p2f10b proteins | |
WO2005090406A3 (en) | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth | |
EP2192132A3 (en) | Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation | |
EP2457928A3 (en) | Monoclonal human tumor-specific antibody | |
IL163902A0 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
WO2001068708A3 (en) | Human and humanized fap-alpha-specific antibodies | |
WO2007075921A3 (en) | De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy | |
WO2005118864A3 (en) | Antibodies and related molecules that bind to psca proteins | |
MXPA05008794A (en) | Glycorpotein antigen sima135 expressed in metastatic human tumor cells. | |
WO2008013954A3 (en) | Tyrosine phosphorylation sites | |
WO2008013934A3 (en) | Tyrosine phosphorylation sites | |
AU2003227148A1 (en) | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer | |
WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
WO2004018519A3 (en) | Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor | |
WO2005048822A3 (en) | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002769304 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002308562 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/009924 Country of ref document: MX Ref document number: 1020037014151 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2446087 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 02809297X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002587625 Country of ref document: JP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003/09380 Country of ref document: ZA Ref document number: 200309380 Country of ref document: ZA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002769304 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref document number: 2002308562 Country of ref document: AU Date of ref document: 20020503 Kind code of ref document: B |